Asthma Management FeNO Devices Market

USD 58.8 million in 2026 to USD 211.8 million by 2036 at a 13.7% CAGR.

• As per Fact.MR analysis, the asthma management FeNO devices market was valued at USD 51.7 million in 2025.
• Demand will grow from USD 58.8 million in 2026 to USD 211.8 million as clinicians place greater emphasis on objective assessment of airway inflammation and treatment monitoring.
• The forecast records a 13.7% CAGR from 2026 to 2036, supported by the use of FeNO testing in specialist respiratory care and wider adoption in primary care.

Source: Fact.MR analysis. Updated Nov 9, 2026

What are the defining numbers behind Asthma Management FeNO Devices Market growth?

Absolute opportunity: USD 153.0 million between 2026 and 2036.

• Demand Drivers in the Market
  • Greater use of objective asthma assessment has increased the demand for Asthma Management FeNO Devices. The Respiratory specialists are increasingly using FeNO measurements alongside symptoms and lung function tests to assess airway inflammation. The 2024 BTS/NICE/SIGN guideline includes FeNO measurement in the diagnostic pathway for suspected asthma. It specifies a FeNO threshold of 50 ppb for adults and 35 ppb for children aged 5 to 16 with a suggestive clinical history [1].  has increased the demand for Asthma Management FeNO Devices. The Respiratory specialists are increasingly using FeNO measurements alongside symptoms and lung function tests to assess airway inflammation. The 2024 joint BTS/NICE/SIGN guideline recommends FeNO measurement as an objective test in adults with suspected asthma and in children aged 5 to 16 [1].
  • Focus on treatment monitoring has driven the demand for the Asthma Management FeNO Devices. FeNO levels can help clinicians assess type 2 airway inflammation and evaluate responses to anti-inflammatory treatment. The 2024 BTS/NICE/SIGN guideline recommends checking FeNO where possible when asthma is uncontrolled. An elevated result may indicate poor treatment adherence or the need to increase the inhaled corticosteroid dose [1].FeNO Devices. FeNO levels can help clinicians assess type 2 airway inflammation and evaluate responses to anti-inflammatory treatment. The American Thoracic Society recommends FeNO use for monitoring airway inflammation in people with asthma, while emphasizing interpretation alongside clinical information [2].
  • Expansion of primary care testing has created lucrative opportunity for the growth of the market. FeNO devices can help bring objective respiratory assessment closer to the patient. NIOX and Bosch offer systems designed for clinical use, while Bosch also provides a home-monitoring device connected to a patient app [3]. Wider availability can support adoption beyond specialist pulmonology centers.
  • Demand for pediatric respiratory assessment has driven the growth of the market. FeNO testing can be useful in pediatric asthma evaluation when a child can perform the required breathing maneuver. Device manufacturers have developed patient interfaces and testing protocols to support younger users. NIOX VERO, for example, is indicated for FeNO measurements in patients aged four years and older, subject to the product instructions [5].
  • Development of home and remote monitoring supports the market growth. Connected FeNO devices can support longitudinal tracking between clinical visits. Bosch's Vivatmo system combines a professional device, a home measurement device, and an app-based asthma diary [4]. This creates opportunities for monitoring models that connect patients with healthcare professionals.
• Key Segments Analyzed
  • By Asthma FeNO Care Setting: Allergy Clinics are projected to account for 29.5% of the market in 2026, reflecting the role of airway inflammation assessment in allergy-related respiratory care.
  • By Clinical Care Location: Primary Care is expected to lead with a 25.1% share in 2026 as FeNO testing becomes more accessible outside specialist respiratory centers.
  • By Device Consumable Model: Single-Use Mouthpieces are set to capture 32.2% of the market in 2026, supported by infection-control requirements and patient-specific testing accessories.
  • By Patient / Use Profile: Longitudinal Monitoring is projected to represent 24.8% of the market in 2026, reflecting the use of repeat measurements to assess changes in airway inflammation over time.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “FeNO devices can strengthen asthma management by giving clinicians an objective measure of airway inflammation alongside conventional assessment. Wider adoption will depend on making testing accessible in primary care while maintaining consistent measurement quality and appropriate clinical interpretation.”
• Strategic Implications
  • FeNO device manufacturers should develop compact systems that fit primary care workflows and require limited maintenance.
  • Consumable suppliers need to maintain reliable availability of patient-specific mouthpieces, filters, and other approved accessories.
  • Healthcare providers can combine FeNO results with symptoms, lung function, and treatment history rather than relying on a single biomarker.
  • Device developers must improve home-monitoring connectivity while ensuring that patients understand when professional review is required.
  • Manufacturers targeting pediatric clinics need to provide age-appropriate instructions and testing interfaces that support reliable patient cooperation.

China is projected to record a 16.0% CAGR through 2036. The USA is set to post 15.5%, followed by the UK at 14.9%. Germany is forecast to advance at 14.6%, while Japan is expected to register 12.8%.

Fact.MR finds that Allergy Clinics lead the Asthma FeNO Care Setting segment at 29.5%; Primary Care leads the Clinical Care Location segment at 25.1%; Single-Use Mouthpieces lead the Device Consumable Model segment at 32.2%; and Longitudinal Monitoring leads the Patient / Use Profile segment at 24.8%.

Which Asthma FeNO Care Setting dominates?

Allergy Clinics are set to hold a 29.5% share in 2026.

Source: Fact.MR analysis. Updated Nov 9, 2026

Allergy clinics evaluate patients with suspected allergic airway conditions and may use FeNO measurements as part of a broader assessment of airway inflammation. The test can provide additional information when clinicians investigate asthma symptoms and allergic triggers. Pulmonology specialists also use FeNO testing to support asthma assessment and monitor treatment response. Pediatric clinics represent a relevant setting because asthma frequently begins in childhood, while home monitoring can support repeat measurements between clinical visits.

What leads the Clinical Care Location segment?

Primary Care is set to represent 25.1% share in 2026.

Source: Fact.MR analysis. Updated Nov 9, 2026

Primary care settings can improve access to FeNO testing by enabling clinicians to conduct objective assessments closer to the point of initial consultation. The 2024 BTS/NICE/SIGN guideline includes FeNO among the objective tests used in asthma diagnosis, supporting its relevance beyond specialist centers. Pulmonology clinics remain important for complex cases and treatment monitoring, while allergy and immunology departments use FeNO as part of broader respiratory assessment. Pediatric care and home or remote settings can extend access to selected patient groups.

How does Device Consumable Model shape demand?

Single-Use Mouthpieces are likely to account for 32.2% share in 2026.

Source: Fact.MR analysis. Updated Nov 9, 2026

Single-use mouthpieces support patient-specific testing and infection-control procedures. Bedfont's NObreath FeNO monitor uses single-patient mouthpieces with an integrated infection-control filter. Disposable cartridges and reusable sensors serve different analyzer designs and maintenance models. Calibration supplies and service subscriptions may also contribute to the recurring revenue associated with FeNO systems.

Which Patient / Use Profile accounts for the largest share?

Longitudinal Monitoring is expected to hold a 24.8% share in 2026.

Source: Fact.MR analysis. Updated Nov 9, 2026

Longitudinal monitoring uses repeated FeNO measurements to help clinicians track changes in airway inflammation over time. It can support treatment reviews when interpreted alongside symptoms, medication use, and lung function. Diagnostic evaluation is another major use profile because FeNO can contribute objective information when asthma is suspected. Pediatric and adult asthma groups require suitable testing protocols and patient instructions. COPD is also included in the segmentation, but its revenue attribution should be reviewed because the market title focuses on asthma management and FeNO use in COPD is not equivalent to an asthma-specific device market.

Greater use of objective airway inflammation assessment and connected monitoring supports demand, while equipment costs, clinical training needs, and inconsistent reimbursement can constrain adoption.

Drivers Impact Analysis

Source: Fact.MR analysis. Updated Nov 9, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Nov 9, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Nov 9, 2026

Source: Fact.MR analysis. Updated Nov 9, 2026

What supports United States adoption?

15.5% CAGR, supported by a substantial asthma patient population and established respiratory care infrastructure.

The United States has a significant population requiring ongoing asthma assessment. The CDC reported that 8.4% of the U.S. population, or approximately 27.8 million people, had current asthma in 2023 [7]. This creates a large potential base for objective respiratory assessment and monitoring. FeNO analyzers can serve specialist clinics and primary care providers that want additional information about airway inflammation. NIOX and Bosch offer FeNO systems designed for professional use, while home-monitoring options can support selected patients under clinical supervision.

How is Germany developing FeNO device adoption?

14.6% CAGR, shaped by respiratory care demand and established specialist healthcare services.

Germany has a substantial asthma patient population and an established network of specialist medical services. The German Federal Ministry of Health's public health portal reports that approximately 6% of adults and 4% of children have asthma [8]. FeNO testing can support assessment of airway inflammation in specialist respiratory care and selected primary care settings. Manufacturers can target hospitals, pulmonology clinics, and allergy practices with devices that provide consistent measurements and straightforward maintenance.

What supports United Kingdom adoption?

14.9% CAGR, led by guideline recognition of FeNO testing in asthma diagnosis.

The UK offers a favorable clinical environment for FeNO devices because national guidance includes the test in objective asthma assessment. The BTS/NICE/SIGN guideline recommends FeNO measurement for adults with suspected asthma and for children aged 5 to 16. This provides a clinical basis for adoption across primary care and specialist settings. Bedfont's NObreath and NIOX systems can serve providers seeking point-of-care measurements, while single-use accessories support patient-specific testing workflows [6] .

How is China building adoption?

16.0% CAGR, driven by opportunities to expand objective respiratory testing across clinical settings.

China's opportunity is linked to the need for accessible respiratory assessment across hospitals and specialist clinics. Wider availability of FeNO analyzers can help clinicians incorporate airway inflammation measurements into asthma evaluation and monitoring. Sunvou Medical Electronics offers FeNO analyzer models for clinical respiratory care, including the HA1101 and CA2122 [9]. Device suppliers can strengthen market access through local distribution, service support, and training for respiratory professionals.

What supports Japan adoption?

12.8% CAGR, backed by demand for respiratory assessment and interest in patient monitoring.

Japan's opportunity is linked to its established healthcare infrastructure and demand for consistent management of chronic respiratory conditions. FeNO testing can provide additional information about airway inflammation when used alongside symptoms and lung function measures. Suppliers can target pulmonology and allergy clinics with compact analyzers and reliable consumable supply. Home monitoring may also provide an opportunity where clinicians determine that repeat measurements can improve follow-up.

Fact.MR profiles NIOX Group plc, Bedfont Scientific Ltd., Bosch Healthcare Solutions GmbH, ECO MEDICS AG, and Sunvou Medical Electronics Co., Ltd. across FeNO measurement, respiratory diagnostics, and asthma monitoring.

NIOX Group plc is a direct FeNO device provider through its NIOX product portfolio. NIOX VERO is a point-of-care analyzer designed to measure fractional exhaled nitric oxide, while its system uses sensors and patient-specific accessories. The company emphasizes measurement quality, patient guidance, and the role of FeNO in asthma assessment and monitoring.

Bedfont Scientific Ltd. supplies the NObreath FeNO monitor. Its product uses a single-patient mouthpiece with an integrated infection-control filter. Bedfont also provides consumables and supports international distribution through a network of distributors. Its offering gives the company a direct position in portable FeNO testing and associated recurring consumables.

Bosch Healthcare Solutions GmbH offers the Vivatmo system, which includes Vivatmo pro for clinical settings and Vivatmo me for home FeNO measurement. The system also includes an app-based asthma diary for tracking patient measurements and related information. Bosch's product model connects professional assessment with home monitoring and physician-supervised follow-up.

ECO MEDICS AG supplies pulmonary diagnostic systems with FeNO analysis capabilities. Its ANALYZER CLD 88 sp supports single- and multiple-breath FeNO measurements and offers applications for bronchial, alveolar, and nasal nitric oxide analysis. The company also provides software for analyzing and reporting respiratory test results.

Sunvou Medical Electronics Co., Ltd. offers FeNO analyzers for clinical respiratory care. Its product range includes the HA1101, CA2122, TM2120, and TM1100 models, with configurations for different nitric oxide measurement applications. The company also describes bronchial, alveolar, and nasal nitric oxide assessment capabilities across its product portfolio.

Competition in the market depends on measurement accuracy, ease of patient testing, device portability, consumable requirements, and service support. Manufacturers need to ensure that their analyzers meet relevant regulatory requirements in each market. They also need to help healthcare professionals interpret results appropriately and integrate FeNO measurements into broader asthma management workflows.

Key companies profiled in the Asthma Management FeNO Devices Market include:

• NIOX Group plc
• Bedfont Scientific Ltd.
• Bosch Healthcare Solutions GmbH
• ECO MEDICS AG
• Sunvou Medical Electronics Co., Ltd.

• [1] National Institute for Health and Care Excellence. (2024, November 27). Asthma: Diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) – Recommendations (NG245).
• [2] National Institute for Health and Care Excellence. (2024, November 27). Asthma pathway (BTS, NICE, SIGN) (NG244).
• [3] NIOX Group plc. (n.d.). NIOX® Technology: The FeNO technology of choice.
• [4] Bosch Healthcare Solutions GmbH. (n.d.). The Vivatmo System.
• [5] NIOX Group plc. (n.d.). NIOX VERO® User Manual – English.
• [6] Bedfont Scientific Ltd. (n.d.). NObreath® FeNO Monitor.
• [7] Centers for Disease Control and Prevention. (n.d.). Most Recent Asthma Data.
• [8] Federal Ministry of Health, Germany. (n.d.). Asthma: Symptoms, outlook, and treatment.
• [9] Sunvou Medical Electronics Co., Ltd. (n.d.). Respiratory FeNO testing and analyzer products.

• The report describes how FeNO devices support asthma assessment and monitoring across specialist and primary care settings.
• Segment analysis compares allergy clinics, pulmonology specialists, primary care, pediatric clinics, and home monitoring.
• Consumable analysis examines single-use mouthpieces, disposable cartridges, reusable sensors, calibration supplies, and service subscriptions.
• Patient and use-profile analysis considers longitudinal monitoring, pediatric asthma, adult asthma, and diagnostic evaluation.
• Country analysis discusses the USA, Germany, UK, China, and Japan alongside respiratory care and clinical guideline indicators.
• The competitive overview profiles NIOX Group, Bedfont Scientific, Bosch Healthcare Solutions, ECO MEDICS, and Sunvou Medical Electronics.

The market covers medical devices that measure fractional exhaled nitric oxide in human breath to support asthma assessment and monitoring. FeNO measurement provides information about airway inflammation and can help clinicians assess type 2 inflammatory activity. The market includes professional analyzers and relevant home-monitoring devices, along with associated consumables and services where they form part of the device offering.

FeNO results are interpreted alongside patient symptoms, clinical history, lung function measurements, and treatment information. They are not a standalone confirmation of asthma.

What is included in the scope?

Included products are FeNO analyzers and monitoring systems intended for clinical or supervised home use.

The scope includes devices used in pulmonology clinics, allergy and immunology practices, primary care centers, pediatric clinics, and home-monitoring programs. Associated patient mouthpieces, disposable cartridges, sensors, calibration supplies, and service arrangements are included when linked to the analyzer platform.

What is excluded from the scope?

The analysis excludes general spirometers and peak-flow meters that do not measure FeNO.

Standalone blood eosinophil tests, allergy testing kits, inhalers, nebulizers, and unrelated respiratory monitoring equipment are excluded. General nitric oxide analyzers used solely for industrial, laboratory, or environmental applications are also outside the market boundary. COPD-related FeNO use should be treated separately unless the market definition explicitly includes non-asthma respiratory applications.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.